Clinical trial NCT04835948 - References

Immunosuppression — Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplantation

Citation(s)

•   Abouna GM, al-Abdullah IH, Kelly-Sullivan D, Kumar MS, Loose J, Phillips K, Yost S, Seirka D
  Randomized clinical trial of antithymocyte globulin induction in renal transplantation comparing a fixed daily dose with dose adjustment according to T cell monitoring. Transplantation. 1995 Jun 15;59(11):1564-8.
•   Alangaden GJ, Thyagarajan R, Gruber SA, Morawski K, Garnick J, El-Amm JM, West MS, Sillix DH, Chandrasekar PH, Haririan A
  Infectious complications after kidney transplantation: current epidemiology and associated risk factors. Clin Transplant. 2006 Jul-Aug;20(4):401-9.
•   Bauer AC, Franco RF, Manfro RC
  Immunosuppression in Kidney Transplantation: State of the Art and Current Protocols. Curr Pharm Des. 2020;26(28):3440-3450. doi: 10.2174/1381612826666200521142448. Review.
•   Bishop G, Cosimi AB, Voynow NK, Whelchel JD, Wortis HH
  Effect of immunosuppressive therapy for renal allografts on the number of circulating sheep red blood cells rosetting cells. Transplantation. 1975 Aug;20(2):123-9.
•   Clesca P, Dirlando M, Park SI, García R, Ferraz E, Pinheiro-Machado PG, Kushnaroff L, Tedesco-Silva H Jr, Medina-Pestana JO
  Thymoglobulin and rate of infectious complications after transplantation. Transplant Proc. 2007 Mar;39(2):463-4.
•   Djamali A, Turc-Baron C, Portales P, Leverson G, Chong G, Clot J, Mourad G
  Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000 Mar 15;69(5):799-805.
•   First MR
  Immunologically high-risk recipient strategies. Transplant Proc. 1999 Feb-Mar;31(1-2):243-6. Review.
•   Gaber AO, Knight RJ, Patel S, Gaber LW
  A review of the evidence for use of thymoglobulin induction in renal transplantation. Transplant Proc. 2010 Jun;42(5):1395-400. doi: 10.1016/j.transproceed.2010.04.019. Review.
•   Grandtnerovà B, Mocikovà H, Kohutovà M
  CD2+, CD3+, and CD19+ depletion after a course of antithymocyte globulin for a steroid-resistant rejection. Transplant Proc. 1997 Nov;29(7):2958-9.
•   Kho MM, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W
  The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012 Jun;26(4):186-90. doi: 10.1016/j.trim.2012.02.003. Epub 2012 Mar 5.
•   Krasinskas AM, Kreisel D, Acker MA, Bavaria JE, Pochettino A, Kotloff RM, Arcasoy S, Blumenthal N, Kamoun M, Moore JS, Rosengard BR
  CD3 monitoring of antithymocyte globulin therapy in thoracic organ transplantation. Transplantation. 2002 Apr 27;73(8):1339-41.
•   Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y
  New directions for rabbit antithymocyte globulin (Thymoglobulin(®)) in solid organ transplants, stem cell transplants and autoimmunity. Drugs. 2014 Sep;74(14):1605-34. doi: 10.1007/s40265-014-0277-6. Review. Erratum in: Drugs. 2014 Dec;74(18):2217.
•   Nafar M, Dalili N, Poor-Reza-Gholi F, Ahmadpoor P, Samadian F, Samavat S
  The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant. 2017 Jun;31(6). doi: 10.1111/ctr.12977. Epub 2017 Apr 18.
•   Nankivell BJ, Alexander SI
  Rejection of the kidney allograft. N Engl J Med. 2010 Oct 7;363(15):1451-62. doi: 10.1056/NEJMra0902927. Review.
•   Peddi VR, Bryant M, Roy-Chaudhury P, Woodle ES, First MR
  Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002 May 15;73(9):1514-8.
•   Taylor DO, Kfoury AG, Pisani B, Hammond EH, Renlund DG
  Antilymphocyte-antibody prophylaxis: review of the adult experience in heart transplantation. Transplant Proc. 1997 Dec;29(8A):13S-15S. Review.
•   Tedesco-Silva H, Felipe C, Ferreira A, Cristelli M, Oliveira N, Sandes-Freitas T, Aguiar W, Campos E, Gerbase-DeLima M, Franco M, Medina-Pestana J
  Reduced Incidence of Cytomegalovirus Infection in Kidney Transplant Recipients Receiving Everolimus and Reduced Tacrolimus Doses. Am J Transplant. 2015 Oct;15(10):2655-64. doi: 10.1111/ajt.13327. Epub 2015 May 18.
•   Thiyagarajan UM, Ponnuswamy A, Bagul A
  Thymoglobulin and its use in renal transplantation: a review. Am J Nephrol. 2013;37(6):586-601. doi: 10.1159/000351643. Epub 2013 Jun 12. Review.
•   Uber WE, Uber LA, VanBakel AB, Crumbley AJ 3rd, Pereira NL, Ikonomidis JS, Feldman DS
  CD3 monitoring and thymoglobulin therapy in cardiac transplantation: clinical outcomes and pharmacoeconomic implications. Transplant Proc. 2004 Dec;36(10):3245-9.
•   Wang CJ, Tuffaha A, Zhang D, Diederich DA, Wetmore JB
  A CD3+ count-based thymoglobulin induction regimen permits delayed introduction of calcineurin inhibitors in kidney transplantation. Clin Transplant. 2012 Nov-Dec;26(6):900-9. doi: 10.1111/j.1399-0012.2012.01656.x. Epub 2012 Jun 4.
•   Yang JW, Wang JN, Men TY, Zhang XM, Li XD, Shen B, Li GY, Chen DD
  Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience. Ann Transplant. 2014 Jun 6;19:277-82. doi: 10.12659/AOT.890069.

Study of the Efficacy of Single Dose Anti-thymocyte Globulin in the Modulation of T Lymphocytes in Kidney Transplant Outcomes

Details for clinical trial NCT04835948